New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMelanotan II vs Vesilute

Melanotan II vs Vesilute

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
Melanotan II
Anti-Aging & Longevity
Vesilute
Summary
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that stimulates melanin production (skin tanning), suppresses appetite, and enhances sexual function. It is not FDA-approved and has significant safety concerns including mole changes and cardiovascular effects.
Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
Half-Life
1–2 hours
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
0.25–0.5 mg
10 mg per day
Frequency
Once daily
Daily for 10–30 days
Key Benefits
  • Promotes skin tanning and melanin production
  • Reduces UV exposure needed to tan
  • Enhances libido and sexual function
  • May suppress appetite
  • Faster, deeper tan development
  • Longer-lasting tan maintenance
  • Potential photoprotective effects
  • Supports retinal photoreceptor cell function and survival
  • May slow progression of age-related macular degeneration
  • Reduces retinal cell apoptosis from oxidative stress and aging
  • Anti-aging effects on retinal pigment epithelium
  • Potential support in diabetic retinopathy management
  • Preserves visual acuity with aging
  • Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
Side Effects
  • Nausea (very common, especially in first days)
  • Facial flushing
  • Spontaneous erections in men
  • Darkening or changes in existing moles (monitor closely)
  • +3 more
  • Generally well tolerated
  • Mild injection site reactions
  • No significant ocular adverse events reported at standard doses
Stacks With